Revolution Medicines (RVMD) provides pipeline updates
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/10/2026
- S&P 500, Dow futures attempt recovery ahead of inflation report
- Oracle raises full year profit guidance, stock rises after hours
- Oil surges 6%, Brent and US crude both surpass $100 on more tanker attacks
- Analysts split on Apple after foldable iPhone Duo debut
- JPMorgan upgrades Meta on AI models and agents, sees 'meaningful headroom'
- S&P 500 ends down as oil tops $100 per barrel
- White House copper tariff plan stalls amid affordability concerns, sources say
- Trump promises $5,000 payout to U.S. adults if Republicans win election
- Crude Inventory 0.4M Barrels Last Week - EIA
- Meta stock jumps 5% premarket: Analysts bullish on new Muse AI agent
- After-Hours Movers: ORCL, CRWV, ADBE, ACVA, CPRT, ZUMZ, PMTS, RH
- After-Hours Movers: COO, AEO, NAVN, AVAV, TORO
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
Revolution (RVMD) PT Raised to $55 at JPMorgan
July 16, 2024 5:52 AM EDTJPMorgan analyst Eric Joseph raised the price target on Revolution (NASDAQ: RVMD) to $55.00 (from $42.00) while maintaining a Overweight rating.
The analyst comments "Revisiting our model on the heels of updated phase 1 results for RMC-6236 in 2L+ PDAC, were establishing a Dec-25 price target of $55 (vs prior Dec-24 PT of $42). Key changes to our model include accelerated launch timing (2028 vs 2029 prior) based upon guided... More
Revolution (RVMD) PT Raised to $55 at BofA Securities
July 16, 2024 5:47 AM EDTBofA Securities analyst Alec Stranahan raised the price target on Revolution (NASDAQ: RVMD) to $55.00 (from $48.00) while maintaining a Buy rating.
The analyst comments "RVMD shares were up (+5.5%, NBI: flat) on the back of what we would characterize as a best-case readout for RMC-6236... More
Revolution (RVMD) PT Raised to $73 at Jefferies
July 15, 2024 4:03 PM EDTJefferies analyst Kelly Shi raised the price target on Revolution (NASDAQ: RVMD) to $73.00 (from $63.00) while maintaining a Buy rating.
The analyst comments "With the new PDAC data, we think the odds are tipping even higher now for RVMD's multi-selective RASi to... More
Revolution (RVMD) PT Raised to $57 at Stifel
July 15, 2024 1:42 PM EDTStifel analyst Ben Burnett raised the price target on Revolution (NASDAQ: RVMD) to $57.00 (from $43.00) while maintaining a Buy rating.
The analyst comments "We are reiterating our Buy rating and increasing our TP to $57/share following RMC-6236 (RAS-multi) monotherapy results in PDAC which... More
